VRAX (Virax Biolabs Group) COGS-to-Revenue : 2.20 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group COGS-to-Revenue?

Virax Biolabs Group's Cost of Goods Sold for the six months ended in Sep. 2024 was $0.01 Mil. Its Revenue for the six months ended in Sep. 2024 was $0.01 Mil.

Virax Biolabs Group's COGS to Revenue for the six months ended in Sep. 2024 was 2.20.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Virax Biolabs Group's Gross Margin % for the six months ended in Sep. 2024 was -120.00%.

Virax Biolabs Group COGS-to-Revenue Historical Data

The historical data trend for Virax Biolabs Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group COGS-to-Revenue Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

COGS-to-Revenue

0.54

1.07

1.11

0.67

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
COGS-to-Revenue	Get a 7-Day Free Trial					1.00	1.33	0.86	0.50	2.20

Virax Biolabs Group COGS-to-Revenue Calculation

Virax Biolabs Group's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.105	/	0.156
	=	0.67

Virax Biolabs Group's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.011	/	0.005
	=	2.20

Virax Biolabs Group (NAS:VRAX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Virax Biolabs Group's Gross Margin % for the six months ended in Sep. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.011 / 0.005
	=	-120.00 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Virax Biolabs Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.